Howmet Aerospace Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Howmet Aerospace Inc trades at $224.6 (market cap $88.76B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.61 (market cap $2.27B). The key difference: Howmet Aerospace Inc is far larger — about 39.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HWM | SLS | |
|---|---|---|
Market Cap | $88.76B | $2.27B |
Volume | 2,648,516 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $292.65 | $15.46 |
52-Week Low | $184.09 | $1.39 |
Typical Hold Time | 35 Days | — |
Enterprise Value | $92.86B | $2.14B |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.50, up 1.26% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace demand driving revenue growth, while institutional interest remains strong with Nykredit's $44.69 million investment in Q2 2026.
Outlook remains positive with 84% analyst buy ratings and $328.10 consensus price target suggesting 45% upside. Key risks include supply chain pressures and competitive threats from SpaceX's in-house initiatives. Earnings growth and defense contracts position HWM for sustained performance despite near-term technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →